Anti-Interferon γ Antibody, clone 1N13 Antibody, ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 1N13 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects human Interferon g.
• Immunogen: GST/His-tagged recombinant mature form of human Interferon g (without the signal peptide and propeptide).
• Application: Quality Control TestingEvaluated by Western Blotting in NK92 cell lysate.Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Interferon in NK92 cell lysate.Tested applicationsWestern Blotting Analysis: A 1:1,000 dilution from a representative lot detected recombinant human Interferon .Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected Interferon in human kidney tissue sections.Affinity Binding Assay: A representative lot of this antibody bound Interferon with a KD of 3.3 x 10-7 in an affinity binding assay.Flow Cytometry Analysis: 1 µg of a representative lot of this antibody detected interferon-gamma in one million human PBMCs.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
• Target description: Interferon g (UniProt: P01579; also known as IFN-gamma, IFN- g , Immune interferon) is encoded by the IFNG gene (Gene ID: 3458) in human. IFN- g is a pleiotropic molecule with anti-proliferative, pro-apoptotic, and anti-tumor properties. It is a type II homodimeric interferon that is synthesized with a signal peptide (aa 1-23) and a propeptide (aa 162-166) that are subsequently cleaved off to produce the mature form. It is secreted predominantly by activated lymphocytes such as CD4 T helper type 1, CD8 cytotoxic T cells, g d T cells, and natural killer cells, and antigen-presenting cells. Its expression is induced by mitogens and cytokines. IFN-g signaling coordinates several biological responses involved in host defense and immune surveillance, establishment of adaptive immunity, and the regulation of inflammation. Its diverse biological activities are initiated by IFN- g -mediated aggregation of at least two different cell surface receptors: IFN gR1 and IFN gR2. IFN- g is reported to activate macrophages toward a pro-inflammatory profile increasing their phagocytic ability and enhancing their microbial killing activity. It is also shown to upregulate cell surface MHC class II on antigen presenting cells, thus promoting peptide-specific activation of CD4 T cells. Mutations in IFNG gene are known to cause aplastic anemia that is characterized by failure of bone marrow to produce adequate number of peripheral blood elements leading to peripheral pancytopenia and hypoplasia. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Castro, F., et al. (2018). Front. Immunol. 9; 847).
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb® formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.